CA3099776A1 - Quinazoline derivatives as antitumor agents - Google Patents

Quinazoline derivatives as antitumor agents Download PDF

Info

Publication number
CA3099776A1
CA3099776A1 CA3099776A CA3099776A CA3099776A1 CA 3099776 A1 CA3099776 A1 CA 3099776A1 CA 3099776 A CA3099776 A CA 3099776A CA 3099776 A CA3099776 A CA 3099776A CA 3099776 A1 CA3099776 A1 CA 3099776A1
Authority
CA
Canada
Prior art keywords
yloxy
triazolo
pyrimidin
amine
methylphenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3099776A
Other languages
English (en)
French (fr)
Inventor
Ding Zhou
Ziqiang CHENG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
Suzhou Zanrong Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suzhou Zanrong Pharma Ltd filed Critical Suzhou Zanrong Pharma Ltd
Publication of CA3099776A1 publication Critical patent/CA3099776A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CA3099776A 2018-09-18 2019-09-17 Quinazoline derivatives as antitumor agents Pending CA3099776A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CNPCT/CN2018/106098 2018-09-18
CN2018106098 2018-09-18
CNPCT/CN2019/091078 2019-06-13
CN2019091078 2019-06-13
PCT/CN2019/106233 WO2020057511A1 (en) 2018-09-18 2019-09-17 Quinazoline derivatives as antitumor agents

Publications (1)

Publication Number Publication Date
CA3099776A1 true CA3099776A1 (en) 2020-03-26

Family

ID=69888359

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3099776A Pending CA3099776A1 (en) 2018-09-18 2019-09-17 Quinazoline derivatives as antitumor agents

Country Status (19)

Country Link
US (2) US11723908B2 (OSRAM)
EP (3) EP4360713B1 (OSRAM)
JP (3) JP7546550B2 (OSRAM)
KR (2) KR102889933B1 (OSRAM)
CN (2) CN112654612A (OSRAM)
AU (2) AU2019341273B2 (OSRAM)
CA (1) CA3099776A1 (OSRAM)
DK (2) DK4360713T3 (OSRAM)
ES (2) ES2971927T3 (OSRAM)
FI (2) FI3853220T3 (OSRAM)
HR (2) HRP20240293T1 (OSRAM)
HU (2) HUE065578T2 (OSRAM)
LT (2) LT4360713T (OSRAM)
PL (2) PL4360713T3 (OSRAM)
PT (2) PT4360713T (OSRAM)
RS (2) RS66314B1 (OSRAM)
SI (2) SI3853220T1 (OSRAM)
SM (1) SMT202400524T1 (OSRAM)
WO (1) WO2020057511A1 (OSRAM)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019196622A1 (zh) * 2018-04-09 2019-10-17 威尚（上海）生物医药有限公司 具有穿过血脑屏障能力的5取代二氟哌啶化合物
CN110357858B (zh) 2018-04-09 2022-02-18 威尚（上海）生物医药有限公司 具有穿过血脑屏障能力的5取代二氟哌啶化合物
HUE065578T2 (hu) * 2018-09-18 2024-06-28 Hoffmann La Roche Kinazolin-származékok, mint daganatellenes szerek
CN111377850B (zh) * 2018-12-31 2022-10-18 艾琪康医药科技（上海）有限公司 一种手性n-取代-3,3-二氟-4-羟基哌啶衍生物及其制备方法
TWI820414B (zh) * 2020-04-17 2023-11-01 大陸商北京賽特明強醫藥科技有限公司 喹唑啉類化合物、製備方法及其應用
CN113527215B (zh) * 2020-04-17 2023-12-05 北京赛特明强医药科技有限公司 一种喹唑啉类化合物、制备方法及其应用
TW202214641A (zh) 2020-06-30 2022-04-16 美商艾瑞生藥股份有限公司 Ｈｅｒ２突變抑制劑
KR20230156767A (ko) * 2021-03-19 2023-11-14 베이징 사이텍-엠큐 파마슈티컬즈 리미티드 퀴나졸린계 화합물, 조성물 및 퀴나졸린계 화합물의 적용
CA3213079A1 (en) 2021-04-13 2022-10-20 Kristin Lynne ANDREWS Amino-substituted heterocycles for treating cancers with egfr mutations
CN117858872A (zh) * 2021-06-22 2024-04-09 缆图药品公司 用于治疗癌症的杂环egfr抑制剂
WO2022271749A1 (en) * 2021-06-22 2022-12-29 Blueprint Medicines Corporation Heterocyclic egfr inhibitors for use in the treatment of cancer
CN117940424A (zh) * 2021-06-22 2024-04-26 缆图药品公司 Egfr抑制剂
CN117836286A (zh) * 2021-06-22 2024-04-05 缆图药品公司 用于治疗癌症的杂环egfr抑制剂
CN115894383B (zh) * 2021-09-30 2025-12-19 北京赛特明强医药科技有限公司 一种喹唑啉类化合物、组合物及其应用
CN115894455B (zh) * 2021-09-30 2024-04-19 北京赛特明强医药科技有限公司 一种喹唑啉类化合物、组合物及其应用
MA66471B1 (fr) * 2021-10-20 2026-02-27 F. Hoffmann-La Roche Ag Formes cristallines de dérivés de quinazoline, leur préparation, leur composition et leur utilisation
WO2023138675A1 (zh) * 2022-01-21 2023-07-27 默达药物（香港）有限公司 喹啉化合物及其用途
US20230293539A1 (en) * 2022-03-14 2023-09-21 Huyabio International, Llc Mll1-wdr5 protein-protein interaction inhibitor compounds and uses thereof
JP2025509995A (ja) * 2022-03-28 2025-04-11 江蘇恒瑞医薬股▲ふん▼有限公司 含窒素複素環系化合物、その調製方法及びその医薬的使用
CN115650977A (zh) * 2022-10-09 2023-01-31 广东润兴生物科技有限公司 一种妥卡替尼的合成方法
TW202446386A (zh) * 2023-04-14 2024-12-01 大陸商迪哲（江蘇）醫藥股份有限公司 喹唑啉ＥｒｂＢ抑制劑的藥物形式
WO2024249642A1 (en) * 2023-06-02 2024-12-05 Acerand Therapeutics (Hong Kong) Limited Egfr inhibitors
AU2024353411A1 (en) * 2023-09-27 2026-05-07 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Pharmaceutically acceptable salt and crystalline form of quinazoline derivative, and use thereof
WO2025195333A1 (en) 2024-03-19 2025-09-25 F. Hoffmann-La Roche Ag Pharmaceutical formulation of erbb2 inhibitors

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0171407B1 (en) 1984-01-30 1993-11-18 Imperial Cancer Research Technology Limited Improvements relating to growth factors
US5401638A (en) 1986-06-04 1995-03-28 Oncogene Science, Inc. Detection and quantification of neu related proteins in the biological fluids of humans
US6743782B1 (en) 1987-10-28 2004-06-01 Wellstat Therapeutics Corporation Acyl deoxyribonucleoside derivatives and uses thereof
EP0494135B1 (en) 1989-09-29 1996-04-10 Oncogene Science, Inc. Human "neu" related protein p100 and use of the same for detecting preneoplastic or neoplastic cells in a human
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
WO1997030035A1 (en) 1996-02-13 1997-08-21 Zeneca Limited Quinazoline derivatives as vegf inhibitors
ES2169355T3 (es) 1996-03-05 2002-07-01 Astrazeneca Ab Derivados de 4-anilinoquinazolina.
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
US5994071A (en) 1997-04-04 1999-11-30 Albany Medical College Assessment of prostate cancer
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
IL152682A0 (en) 2000-05-31 2003-06-24 Astrazeneca Ab Indole derivatives with vascular damaging activity
NZ522568A (en) 2000-06-22 2004-12-24 Pfizer Prod Inc Substituted bicyclic derivatives for the treatment of abnormal cell growth
BR0112224A (pt) 2000-07-07 2003-06-10 Angiogene Pharm Ltd Composto, composição farmacêutica, uso de um composto ou de um sal, solvato ou pró-droga farmaceuticamente aceitável do mesmo, e, processo para preparar um composto
HUP0301742A3 (en) 2000-07-07 2005-08-29 Angiogene Pharm Ltd Colchinol derivatives as angiogenesis inhibitors, process for producing them, pharmaceutical compositions containing them and their use
JP2005515176A (ja) 2001-11-03 2005-05-26 アストラゼネカ アクチボラグ 抗腫瘍剤としてのキナゾリン誘導体
US7235537B2 (en) 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
WO2004000529A1 (de) 2002-06-24 2003-12-31 Fagerdala Deutschland Gmbh Verfahren zur herstellung von bauteilen aus hochgradig lignocellulosefaser-gefüllten thermoplasten
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
JP4828421B2 (ja) 2003-08-14 2011-11-30 アレイ バイオファーマ、インコーポレイテッド 受容体チロシンキナーゼ阻害剤としてのキナゾリン誘導体
CA2755268C (en) * 2005-11-15 2013-12-31 Array Biopharma, Inc. Erbb inhibitors
BRPI0720169A2 (pt) 2006-12-12 2013-12-24 Takeda Pharmaceutical Composto ou um sal do mesmo, prodroga, agente farmacêutico, método para a profilaxia ou tratamento de câncer, e, uso do composto
WO2017148391A1 (zh) * 2016-03-01 2017-09-08 上海医药集团股份有限公司 一种含氮杂环化合物、制备方法、中间体、组合物和应用
EP3516071B1 (en) 2016-09-22 2021-02-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of lung cancer
CN109422755B (zh) * 2017-09-01 2023-07-04 上海医药集团股份有限公司 一种含氮杂环化合物、制备方法、中间体、组合物和应用
WO2019120213A1 (zh) 2017-12-19 2019-06-27 南京明德新药研发股份有限公司 喹唑啉衍生物及其应用
US12030897B2 (en) 2018-05-08 2024-07-09 Medshine Discovery Inc. Pyrrolo[2,1-f][1,2,4]triazine derivatives serving as selective HER2 inhibitors and application thereof
AR117424A1 (es) * 2018-05-08 2021-08-04 Dizal Jiangsu Pharmaceutical Co Ltd Inhibidores de los receptores erbb
HUE065578T2 (hu) * 2018-09-18 2024-06-28 Hoffmann La Roche Kinazolin-származékok, mint daganatellenes szerek

Also Published As

Publication number Publication date
SI4360713T1 (sl) 2025-02-28
HRP20240293T1 (hr) 2024-05-24
FI4360713T3 (fi) 2024-12-27
EP4360713A2 (en) 2024-05-01
RS65413B1 (sr) 2024-05-31
EP4523755A3 (en) 2025-06-11
PL3853220T3 (pl) 2024-09-02
HUE065578T2 (hu) 2024-06-28
JP2026009898A (ja) 2026-01-21
PL4360713T3 (pl) 2025-06-23
LT4360713T (lt) 2025-01-10
US11723908B2 (en) 2023-08-15
KR20210061329A (ko) 2021-05-27
EP3853220A1 (en) 2021-07-28
DK3853220T3 (da) 2024-03-04
JP7546550B2 (ja) 2024-09-06
JP2024164018A (ja) 2024-11-26
SMT202400524T1 (it) 2025-01-14
CN118255772A (zh) 2024-06-28
US20230293533A1 (en) 2023-09-21
RS66314B1 (sr) 2025-01-31
AU2019341273A1 (en) 2020-11-19
AU2024204847A1 (en) 2024-08-01
KR20250171398A (ko) 2025-12-08
WO2020057511A1 (en) 2020-03-26
HUE069764T2 (hu) 2025-04-28
ES2971927T3 (es) 2024-06-10
CN112654612A (zh) 2021-04-13
EP4360713B1 (en) 2024-10-30
ES3007082T3 (en) 2025-03-19
SI3853220T1 (sl) 2024-04-30
EP4523755A2 (en) 2025-03-19
FI3853220T3 (fi) 2024-02-22
EP4360713A3 (en) 2024-05-22
DK4360713T3 (da) 2025-01-06
US20210386742A1 (en) 2021-12-16
HRP20241743T1 (hr) 2025-02-28
AU2019341273B2 (en) 2024-09-26
EP3853220B1 (en) 2024-01-03
JP2022501338A (ja) 2022-01-06
KR102889933B1 (ko) 2025-11-24
PT4360713T (pt) 2025-01-07
EP3853220A4 (en) 2022-06-22
PT3853220T (pt) 2024-02-22
LT3853220T (lt) 2024-03-12

Similar Documents

Publication Publication Date Title
AU2019341273B2 (en) Quinazoline derivatives as antitumor agents
CA3226720A1 (en) Kras g12d inhibitors and uses thereof
JP7706585B2 (ja) 毛細血管拡張性運動失調症変異（ＡＴＭ）キナーゼの選択的調節物質としての１－イソプロピル－３－メチル－８－（ピリジン－３－イル）－１，３－ジヒドロ－２Ｈ－イミダゾ［４，５－ｃ］シンノリン－２－オンおよびその使用
BRPI0618668A2 (pt) composto, composição, método pra o tratamento de uma doença hiperproliferativa em um mamìfero, uso de um composto e método para a preparação de um composto
AU2025203211A1 (en) ErbB RECEPTOR INHIBITORS AS ANTI-TUMOR AGENTS
CN120265635A (zh) 抗癌核激素受体靶向化合物
CA3213823A1 (en) Selective modulators of ataxia telangiectasia mutated (atm) kinase and uses thereof
HK40108721A (zh) 作为抗肿瘤剂的喹唑啉衍生物
TW202545531A (zh) 氮—喹唑啉化合物之使用方法

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240215

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240826

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240826

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240826

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250321

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250714

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250716

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250728

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250728

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250821

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250821

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20260325